Targets › STING1
1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Apr 2029.
Key innate immune signaling adapter that promotes the production of type I interferon (IFN-alpha and IFN-beta) in response to the presence of DNA from bacteria and viruses in the cytosol. Innate immune response is triggered by non-CpG double-stranded DNA from viruses and bacteria delivered to the cytoplasm, which induces production of cyclic dinucleotides that bind and activate STING1: STING1 recognizes and binds…. (UniProt, Q86WV6)
Open in Phaseline: the race on STING1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chinese PLA General Hospital | Manganese Chloride cGAS-STING pathway activator | CGAS, STING1 | Phase 3 | Ovarian Cancer | Apr 2029 |
Ovarian Cancer (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.